Cargando…
Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
Novel adjuvant strategies are needed to optimize outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). The adjuvant treatment of ROS Proto-Oncogene 1 (ROS1) fusion-positive resected NSCLC is challenging because there is no curative confirmed rand...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921990/ https://www.ncbi.nlm.nih.gov/pubmed/35299735 http://dx.doi.org/10.3389/fonc.2022.837219 |
_version_ | 1784669433679052800 |
---|---|
author | Chen, An-guo Chen, Dong-sheng Li, Si Zhao, Le-le Xiao, Ming-zhe |
author_facet | Chen, An-guo Chen, Dong-sheng Li, Si Zhao, Le-le Xiao, Ming-zhe |
author_sort | Chen, An-guo |
collection | PubMed |
description | Novel adjuvant strategies are needed to optimize outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). The adjuvant treatment of ROS Proto-Oncogene 1 (ROS1) fusion-positive resected NSCLC is challenging because there is no curative confirmed randomized controlled trial. Next-generation sequencing (NGS) and immunohistochemistry (IHC) staining were performed on the biopsy sample. In this case, we identified a novel LDLR–ROS1 fusion in a resectable stage IIIA NSCLC patient. The patient received crizotinib as adjuvant treatment and achieved recurrence-free survival (RFS) for 29 months, without significant symptoms of toxicity. In this case, we report a novel LDLR–ROS1 fusion responding to crizotinib in a patient with lung adenocarcinoma, supporting the use of adjuvant treatment with the ROS1 inhibitor exerting clinical survival benefit in ROS1 fusion-positive resected NSCLC. |
format | Online Article Text |
id | pubmed-8921990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89219902022-03-16 Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion Chen, An-guo Chen, Dong-sheng Li, Si Zhao, Le-le Xiao, Ming-zhe Front Oncol Oncology Novel adjuvant strategies are needed to optimize outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). The adjuvant treatment of ROS Proto-Oncogene 1 (ROS1) fusion-positive resected NSCLC is challenging because there is no curative confirmed randomized controlled trial. Next-generation sequencing (NGS) and immunohistochemistry (IHC) staining were performed on the biopsy sample. In this case, we identified a novel LDLR–ROS1 fusion in a resectable stage IIIA NSCLC patient. The patient received crizotinib as adjuvant treatment and achieved recurrence-free survival (RFS) for 29 months, without significant symptoms of toxicity. In this case, we report a novel LDLR–ROS1 fusion responding to crizotinib in a patient with lung adenocarcinoma, supporting the use of adjuvant treatment with the ROS1 inhibitor exerting clinical survival benefit in ROS1 fusion-positive resected NSCLC. Frontiers Media S.A. 2022-03-01 /pmc/articles/PMC8921990/ /pubmed/35299735 http://dx.doi.org/10.3389/fonc.2022.837219 Text en Copyright © 2022 Chen, Chen, Li, Zhao and Xiao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Chen, An-guo Chen, Dong-sheng Li, Si Zhao, Le-le Xiao, Ming-zhe Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion |
title | Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion |
title_full | Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion |
title_fullStr | Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion |
title_full_unstemmed | Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion |
title_short | Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion |
title_sort | case report: adjuvant crizotinib therapy exerted favorable survival benefit in a resectable stage iiia nsclc patient with novel ldlr–ros1 fusion |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921990/ https://www.ncbi.nlm.nih.gov/pubmed/35299735 http://dx.doi.org/10.3389/fonc.2022.837219 |
work_keys_str_mv | AT chenanguo casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT chendongsheng casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT lisi casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT zhaolele casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT xiaomingzhe casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion |